论文部分内容阅读
采用rIL-2和LAK细胞对原发性肝癌作过继性免疫治疗是目前国内外学者较为关注的课题。保持外源性IL-2的活力,刺激内源性IL-2的产生,增加自体LAK细胞来源以及采用同种LAK细胞等研究有助于肝癌过继性免疫治疗的推广和发展。经肝动脉插管途径可维持局部免疫制剂浓度,有利于配合化疗和栓塞治疗,减少毒副反应。随着现代免疫生物学和生物高技术的发展,寻找更有效的淋巴因子和肿瘤杀伤细胞,寻求更合理的临床免疫治疗方法和途径,将有助于提高肝癌的治疗水平。
The use of rIL-2 and LAK cells for adoptive immunotherapy of primary liver cancer is a topic of concern to scholars at home and abroad. Maintaining the activity of exogenous IL-2, stimulating the production of endogenous IL-2, increasing the source of autologous LAK cells, and adopting the same kind of LAK cells have contributed to the promotion and development of adoptive immunotherapy of liver cancer. The hepatic arterial cannulation can maintain the concentration of local immunological preparations, which is beneficial to the combination of chemotherapy and embolization therapy to reduce toxic and side effects. With the development of modern immunobiology and biological high technology, searching for more effective lymphokine and tumor killer cells and seeking more reasonable methods and approaches for clinical immunotherapy will help improve the therapeutic level of liver cancer.